Combined PET-CT can help diagnose cardiac sarcoidosis.
Combined FDG PET-CT can help uncover secondary sites of cardiac sarcoidosis (CS), according to a study published in the Journal of Nuclear Cardiology.
Researchers from the University of Illinois in Chicago and the University of Texas MD Anderson Cancer Center in Houston performed a retrospective study to investigate the relationship between cardiac and extra-thoracic sarcoid findings on FDG PET-CT using a 72-hour pretest high-fat, high-protein, and very low-carbohydrate (HFHPVLC) diet.
"We wanted to know if patients being evaluated for cardiac sarcoidosis would benefit from more thorough imaging of the body beyond the usual torso scan, using this new technique," co-author Nadera Sweiss, MD, professor of rheumatology in the UIC College of Medicine, said in a release. Sweiss is also director of UI Health's Bernie Mac Sarcoidosis Translational Advanced Research (STAR) Center.
The study included data from 191 consecutive FDG PET-CT scans with 72-hour HFHPVLC diet preparation performed between December 2014 and December 2015 in known sarcoid patients. The researchers categorized cardiac and extra-thoracic sarcoid lesions and they were measured for radiotracer uptake.
The results showed that 188 patients had 191 eligible FDG PET/CT scans (Three follow-up scans):
• 20 (10%) of these scans were positive for CS
• 6 (3%) were indeterminate for CS
• 165 (86%) were negative for CS
Among the 20 scans positive for CS, eight (40%) had findings of both cardiac and extra-thoracic sarcoid.
"This study indicates that more extensive, full-body scans of patients with known cardiac sarcoidosis can uncover secondary sites of the disease in a significant number of patients," Sweiss said in the release. "Knowing there is disease in organs other than the heart changes the way we approach treatment--it allows us to more accurately stage the disease and treat it accordingly." The authors did caution, however, that further testing is required to determine the technique’s ability to detect CS.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.